114290-82-3 Usage
Uses
Used in Pharmaceutical Research and Development:
BOC-PHE-(R)-PHE-OH is utilized as a building block in the synthesis of peptides and proteins for various pharmaceutical applications. Its protective nature for phenylalanine amino acids ensures the integrity of the peptide sequence during synthesis, which is crucial for the development of effective drugs.
Used in Peptide Synthesis:
In the field of peptide synthesis, BOC-PHE-(R)-PHE-OH serves as a crucial component for creating specific peptide sequences. The BOC group's ability to be removed under mild conditions allows for the controlled release of phenylalanine residues, facilitating the precise assembly of peptide structures.
Used in Biochemistry Research:
BOC-PHE-(R)-PHE-OH is employed as a research tool in biochemistry to study the properties and interactions of peptides and proteins. Its role in protecting phenylalanine residues and enabling their controlled release makes it valuable for investigating the structure-function relationships of biologically active molecules.
Used in Drug Discovery:
BOC-PHE-(R)-PHE-OH plays a pivotal role in drug discovery, particularly in the development of peptide-based therapeutics. Its use in the synthesis of peptides with specific sequences and structures aids in the identification and optimization of potential drug candidates with targeted biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 114290-82-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,4,2,9 and 0 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 114290-82:
(8*1)+(7*1)+(6*4)+(5*2)+(4*9)+(3*0)+(2*8)+(1*2)=103
103 % 10 = 3
So 114290-82-3 is a valid CAS Registry Number.
114290-82-3Relevant articles and documents
NOVEL CYP34A-SPECIFIC INHIBITORS AND METHODS OF USING SAME
-
, (2017/03/28)
The present invention includes novel compositions inhibiting CYP3 A4. The present invention further includes a novel method of inhibiting CYP3A4 in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the subject is further administered at least one additional therapeutic agent.
